TABLE 5.

Danofloxacin in vivo and ex vivo AUC_24h/MIC after i.m. administration of danofloxacin at a dose of 1.25 mg/kg^a

Fluid	Danofloxacin AUC24/MIC (h)
	In vivo	Ex vivo for samples collected at the following time after drug administration (h):
		1	3	6	9	12	24	30	36	48
Serum	56.56 ± 9.45	237.87 ± 51.75	165.60 ± 37.39	71.20 ± 19.54	35.33 ± 9.48	20.53 ± 4.97	4.64 ± 0.34b	4.00 ± 0.06c
Exudate	45.61 ± 6.63	44.53 ± 40.94e	69.28 ± 27.62e	67.87 ± 15.87	56.40 ± 7.22e	42.88 ± 8.08e	26.13 ± 9.48e	16.96 ± 9.09	14.40 ± 7.89	11.60 ± 10.04
Transudate	28.19 ± 16.29d,e	13.60 ± 13.05e	27.15 ± 13.49e	34.63 ± 9.99e,f	35.09 ± 8.50d	30.45 ± 5.14f	19.31 ± 5.24g	14.40 ± 5.24	8.64 ± 3.89	8.46 ± 5.41

^aThe values are means ± SDs (n = 6 unless indicated otherwise).

^bn = 5.

^cn = 3.

^dP < 0.01 for comparison of exudate and transudate.

^eP < 0.01 for comparison of serum and exudate or transudate.

^fP < 0.05 for comparison of exudate and transudate.

^gP < 0.05 for comparison of serum and exudate or transudate.